GlassScriptPhysician profile
Liqun Bai
NPI 1609827286
$15,221.74
in general payments reported to CMS, 2019-2025
21 companies · $4,038 in 2025
The $4,038 reported for 2025 was more than what 93% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $62.21 · 2021: $85.49 · 2022: $239 · 2023: $248 · 2024: $273 · 2025: $4,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,618 · Food and Beverage: $902 · Education: $38.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,618.00 |
| Food and Beverage | $901.76 |
| Education | $38.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $10,371.21 | 2019-2025 | Jynarque, Voyxact |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $3,714.69 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $202.21 | 2019-2025 | Lokelma, Farxiga |
| Travere Therapeutics, INC. | $137.03 | 2022-2025 | Filspari |
| Horizon Therapeutics Plc | $136.48 | 2021-2023 | Krystexxa |
| Amgen INC. | $115.01 | 2025 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $66.68 | 2024 | |
| Opko Pharmaceuticals, LLC | $61.65 | 2020-2024 | Rayaldee |
| Vifor Pharma, INC. | $57.10 | 2019-2020 | |
| Glaxosmithkline, LLC. | $45.77 | 2022 | |
| Boston Scientific Corporation | $44.39 | 2023-2024 | |
| Lilly USA, LLC | $43.63 | 2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $39.23 | 2023 | Acthar |
| Renalytix Ai, INC. | $29.23 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Alexion Pharmaceuticals, INC. | $26.73 | 2025 | Ultomiris |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $26.43 | 2019 | |
| Fresenius USA Marketing, INC. | $23.79 | 2025 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $21.64 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.18 | 2024 | Jardiance |
| Calliditas Therapeutics US INC. | $19.98 | 2025 | Tarpeyo |
| Akebia Therapeutics INC | $18.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liqun Bai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.